Form 8-K - Current report:
SEC Accession No. 0000950170-25-103997
Filing Date
2025-08-06
Accepted
2025-08-06 16:07:21
Documents
12
Period of Report
2025-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nmra-20250806.htm   iXBRL 8-K 49189
2 EX-99.1 nmra-ex99_1.htm EX-99.1 165347
3 GRAPHIC img49001591_0.jpg GRAPHIC 27072
  Complete submission text file 0000950170-25-103997.txt   396434

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20250806.xsd EX-101.SCH 43093
14 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20250806_htm.xml XML 6048
Mailing Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472
Business Address 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 251189534
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)